A recent publication on the safety and efficacy of trabectedin treatment for advanced sarcoma:
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3076042/
Partial response or stable disease was seen in 61% of synovial sarcoma patients (11 patients out of 18) in a phase II study.